Secondary Logo

Journal Logo

July/August 2022 - Volume 42 - Issue 4
pp: 339-426





Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users

Landry, Ishani; Hall, Nancy; Aluri, Jagadeesh; More

Journal of Clinical Psychopharmacology. 42(4):365-373, July/August 2022.

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users

Landry, Ishani; Hall, Nancy; Alur, Jagadeesh; More

Journal of Clinical Psychopharmacology. 42(4):374-382, July/August 2022.

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia: A Randomized, Double-Blind, Multicenter Study

Wang, Dandan; Wei, Ning; Hu, Fangzhen; More

Journal of Clinical Psychopharmacology. 42(4):383-390, July/August 2022.


Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series

Béchard, Laurent; Morasse-Bégis, Mahité; Corbeil, Olivier; More

Journal of Clinical Psychopharmacology. 42(4):391-395, July/August 2022.

Esketamine for Unipolar Major Depression With Psychotic Features: A Retrospective Chart Review and Comparison With Nonpsychotic Depression

Souza-Marques, Breno; Telles, Manuela; Leal, Gustavo C.; More

Journal of Clinical Psychopharmacology. 42(4):408-412, July/August 2022.




Duration: 9:40

Clozapine is often prescribed for patients with treatment-resistant schizophrenia, but its use is sometimes discontinued if it is suspected of inducing neutropenia. In this podcast, author Laurent Béchard discusses a consecutive case series published in the July-August 2022 issue of the Journal of Clinical Psychopharmacology assessing the continuation or reintroduction of this drug despite a neutropenia episode. In addition to suggesting further research to better define severe vs. moderate cases, Dr. Béchard proposes the use of pharmacovigilance tools to assess possible causes of neutropenia so clinicians can better determine if this highly effective antipsychotic should remain part of a patient’s treatment plan.

|
Duration: 6:46

A recently published book provides sharp criticism of the modern era of clinical psychopharmacology, questioning the validity of psychiatric diagnoses and the effectiveness of psychopharmacologic treatments. In this podcast, Dr. Anthony J. Rothschild, Editor-in-Chief of the Journal of Clinical Psychopharmacology, offers his perspective on the book, The Rise and Fall of the Age of Psychopharmacology. The book “ignores the fact that many people with serious psychiatric disorders have had their lives dramatically improved by psychotropic medications,” Dr. Rothschild says, noting that he vehemently disagrees with how the book’s author characterizes the profession. The podcast accompanies Dr. Rothschild’s editorial in the July-August 2022 issue of the journal.

|
Show: